When a medication is compounded in the United States, it is prepared under one of two sections of federal law: section 503A or section 503B of the Federal Food, Drug, and Cosmetic Act. Both were added or clarified by the Drug Quality and Security Act of 2013. The labels are unglamorous, but understanding them tells you a lot about how your medication is made, who inspects the facility, and what “regulated” actually means here.
The 503A pharmacy: patient-specific compounding
A 503A pharmacy compounds a medication against a patient-specific prescription — a prescription written for an identified individual. These pharmacies are licensed by their state board of pharmacy and operate under state pharmacy standards and the relevant United States Pharmacopeia (USP) chapters. Oversight is primarily at the state level. The 503A model is the classic picture of compounding: a prescription comes in for a particular person, and the pharmacy prepares it for that person.
The 503B outsourcing facility: batch compounding under CGMP
A 503B “outsourcing facility” is different. Under section 503B(b), a compounder can register with the FDA as an outsourcing facility. Once registered, it may compound in batches — with or without individual prescriptions — and it must comply with Current Good Manufacturing Practice (CGMP) requirements under 21 CFR parts 210 and 211. Critically, 503B facilities are inspected by the FDA on a risk-based schedule, not just by the state. That federal inspection and the CGMP requirement are the headline differences from a 503A pharmacy.
CGMP is the FDA’s baseline quality system for drug manufacturing. Its core principle is that quality is built in throughout the process — controlled raw materials, validated production techniques, trained personnel, facility design — with end-product testing providing additional assurance rather than being the only safeguard. In practice, a 503B facility operates an independent quality control unit that releases each batch only after it meets specifications, monitors its clean areas and personnel, and tests batches for things like identity, strength, sterility, and endotoxins.
A side-by-side summary
- 503A — compounds against a patient-specific prescription; licensed by the state board of pharmacy; operates under state standards and USP chapters; oversight primarily at the state level.
- 503B — registers with the FDA as an outsourcing facility; may compound in batches; must comply with CGMP (21 CFR 210/211); inspected by the FDA on a risk-based schedule.
- Both — are lawful, regulated ways to compound; neither produces an FDA-approved drug; both require a licensed provider to decide treatment is appropriate.
What FDA oversight does — and does not — cover
It is worth being precise here, because this is where marketing copy often overreaches. FDA inspection of a 503B facility and the CGMP requirement are about how the facility operates: quality systems, sterility, traceability, documentation. They do not constitute FDA approval or review of the specific compounded product. The FDA’s sterile/aseptic guidance is also explicitly non-binding — it describes the standards a compliant facility meets, but it does not certify any particular pharmacy or endorse any product.
Separately, the broader U.S. supply chain operates under the Drug Supply Chain Security Act (DSCSA), which requires pharmacies to verify trading partners and keep product-tracing records. That adds traceability and anti-counterfeiting protections — but, again, it is about supply-chain security, not drug approval or efficacy.
Why this matters for your prescription
Knowing whether your medication comes from a 503A pharmacy, a 503B outsourcing facility, or both tells you which oversight model applies and what quality standards the facility operates under. It is a fair, specific question to ask any telehealth provider, and you should always be able to find out exactly which kind of pharmacy stands behind your medicine. Whichever model applies, a prescription is never guaranteed, availability varies by state, and individual results vary.